Humacyte, Inc.

As of August 14, 2023, Humacyte, Inc. is overvalued and has deteriorated to a "does not qualify" rating due to negative profitability metrics, including a price-to-book ratio of 11.15 and a return on equity of -333.22%, while significantly underperforming the S&P 500 with a year-to-date return of -56.24%.

As of May 19, 2025, Humacyte, Inc. shows a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearish sentiment, while the weekly MACD presents mixed signals.

Humacyte, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net profit of $37 million as of March 2025. It has a market cap of $361.43 million, with key metrics indicating it is currently loss-making and has a debt-to-equity ratio of 0.18.

As of Jun 18, Humacyte, Inc. has a market capitalization of 361.43 million and reported net sales of 0.52 million with a net profit of -80.03 million over the last four quarters. Shareholder's funds are at -52.67 million, with total assets of 137.87 million.